MeiraGTx Holdings plc (MGTX)
MGTX Stock Price Chart
Explore MeiraGTx Holdings plc interactive price chart. Choose custom timeframes to analyze MGTX price movements and trends.
MGTX Company Profile
Discover essential business fundamentals and corporate details for MeiraGTx Holdings plc (MGTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jun 2018
Employees
375.00
Website
https://www.meiragtx.comCEO
Alexandria Forbes
Description
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MGTX Financial Timeline
Browse a chronological timeline of MeiraGTx Holdings plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.33, while revenue estimate is $700.00k.
Earnings released on 14 May 2026
EPS came in at -$0.57 falling short of the estimated -$0.43 by -32.56%, while revenue for the quarter reached $293.00k , missing expectations by -98.28%.
Earnings released on 26 Mar 2026
EPS came in at $0.19 surpassing the estimated -$0.60 by +131.67%, while revenue for the quarter reached $75.36m , beating expectations by +5.12k%.
Earnings released on 13 Nov 2025
EPS came in at -$0.62 falling short of the estimated -$0.50 by -24.00%, while revenue for the quarter reached $410.00k , missing expectations by -89.41%.
Earnings released on 14 Aug 2025
EPS came in at -$0.48 surpassing the estimated -$0.52 by +7.69%, while revenue for the quarter reached $3.69m , missing expectations by -43.08%.
Earnings released on 13 May 2025
EPS came in at -$0.51 falling short of the estimated -$0.38 by -34.21%, while revenue for the quarter reached $1.93m , missing expectations by -56.62%.
Earnings released on 13 Mar 2025
EPS came in at -$0.50 falling short of the estimated -$0.48 by -4.17%, while revenue for the quarter reached $21.39m , beating expectations by +1.33k%.
Earnings released on 13 Nov 2024
EPS came in at -$0.54 falling short of the estimated -$0.47 by -14.89%, while revenue for the quarter reached $10.91m , beating expectations by +573.46%.
Earnings released on 12 Aug 2024
EPS came in at -$0.76 falling short of the estimated -$0.31 by -145.16%, while revenue for the quarter reached $282.00k , missing expectations by -97.09%.
Earnings released on 9 May 2024
EPS came in at -$0.77 falling short of the estimated -$0.32 by -140.63%, while revenue for the quarter reached $697.00k , missing expectations by -92.81%.
Earnings released on 14 Mar 2024
EPS came in at -$0.47 falling short of the estimated -$0.46 by -2.17%, while revenue for the quarter reached $2.04m , missing expectations by -68.90%.
Earnings released on 14 Nov 2023
EPS came in at -$0.74 falling short of the estimated -$0.63 by -17.46%, while revenue for the quarter reached $5.10m , beating expectations by +45.80%.
Earnings released on 10 Aug 2023
EPS came in at -$0.53 surpassing the estimated -$0.59 by +10.17%, while revenue for the quarter reached $3.54m , missing expectations by -15.11%.
Earnings released on 11 May 2023
EPS came in at -$0.62 surpassing the estimated -$0.65 by +4.62%, while revenue for the quarter reached $3.33m , missing expectations by -31.40%.
Earnings released on 14 Mar 2023
EPS came in at -$0.58 falling short of the estimated $0.49 by -218.37%, while revenue for the quarter reached $5.29m , missing expectations by -40.72%.
Earnings released on 10 Nov 2022
EPS came in at -$0.83 falling short of the estimated -$0.50 by -66.00%, while revenue for the quarter reached $4.82m , missing expectations by -55.83%.
Earnings released on 11 Aug 2022
EPS came in at -$0.76 falling short of the estimated -$0.58 by -31.03%, while revenue for the quarter reached $10.76m , beating expectations by +53.82%.
Earnings released on 12 May 2022
EPS came in at -$0.70 falling short of the estimated -$0.49 by -42.86%, while revenue for the quarter reached $5.63m , missing expectations by -3.15%.
Earnings released on 10 Mar 2022
EPS came in at -$0.22 surpassing the estimated -$0.49 by +55.10%, while revenue for the quarter reached $21.04m , beating expectations by +415.47%.
Earnings released on 10 Nov 2021
EPS came in at -$0.59 falling short of the estimated -$0.52 by -13.46%, while revenue for the quarter reached $6.95m , beating expectations by +189.46%.
Earnings released on 11 Aug 2021
EPS came in at -$0.46 surpassing the estimated -$0.53 by +13.21%, while revenue for the quarter reached $5.12m , beating expectations by +115.86%.
MGTX Stock Performance
Access detailed MGTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
